Publications

Disk diffusion susceptibility test development for the new glycylcycline, GAR-936. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (3): 249-252

Summation: β-lactam resistance surveillance in the Asia-Western Pacific region. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 333-338

In vitro activity of gatifloxacin tested against anaerobic bacteria by reference agar dilution and Etest methods. by Jones RN, Barrett MS and Pfaller MA published in Clin. Microbiol. Infect. 1999; 5 (9): 577-579

Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: Results from the SENTRY Antimicrobial Surveillance Program (1997). by Jones RN, Winokur PL, Pfaller MA, Doern GV and Barrett T published in Clin. Microbiol. Infect. 1999; 5 (8): 478-487

Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines. by Johnson DM, Jones RN and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1999; 33 (2): 87-91

In vitro evaluation of broad-spectrum β-lactams in the Philippines medical centers: Role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group. by Johnson DM, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 291-297

Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates. by Hayward CL, Erwin ME, Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 34 (2): 99-102

Studies to establish quality control ranges for SB-265805 (LB2030) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods. Quality Control Study Group. by Erwin ME and Jones RN published in J. Clin. Microbiol. 1999; 37 (1): 279-280

Nosocomial bloodstream infections in United States hospitals: A three- year analysis. by Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN and Wenzel RP published in Clin. Infect. Dis. 1999; 29 (2): 239-244

Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). by Doern GV, Jones RN, Pfaller MA and Kugler K published in Antimicrob. Agents Chemother. 1999; 43 (2): 385-389

Assessment of laboratory performance with Streptococcus pneumoniae antimicrobial susceptibility testing in the United States: A report from the College of American Pathologists Microbiology Proficiency Survey Program. by Doern GV, Brueggemann AB, Pfaller MA and Jones RN published in Arch. Pathol. Lab. Med. 1999; 123 (4): 285-289

Bacterial pathogens isolated from patients with skin and soft tissue infections: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). by Doern GV, Jones RN, Pfaller MA, Kugler KC and Beach ML published in Diagn. Microbiol. Infect. Dis. 1999; 34 (1): 65-72

Comparison of activities of broad-spectrum β-lactam compounds against 1,128 Gram-positive cocci recently isolated in cancer treatment centers. by Diekema DJ, Coffman SL, Marshall SA, Beach ML, Rolston KV and Jones RN published in Antimicrob. Agents Chemother. 1999; 43 (4): 940-943

In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America. by Diekema DJ, Pfaller MA, Messer SA, Houston A, Hollis RJ, Doern GV and Jones RN published in Antimicrob. Agents Chemother. 1999; 43 (9): 2236-2239

Antimicrobial activity of gatifloxacin compared to seven other compounds tested against Gram-positive organisms isolated at 10 cancer treatment centers. by Diekema DJ, Jones RN and Rolston KV published in Diagn. Microbiol. Infect. Dis. 1999; 34 (1): 37-43

Survey of bloodstream infections due to Gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. by Diekema DJ, Pfaller MA, Jones RN, Doern GV, Winokur PL, Gales AC, Sader HS, Kugler K, and Beach M published in Clin. Infect. Dis. 1999; 29 (3): 595-607

Comparative activity of clinafloxacin and nine other compounds tested against 2,000 contemporary clinical isolates from patients in United States hospitals. by Deshpande LM, Diekema DJ, and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (1): 81-88

Colony morphology of Candida spp. as a guide to species identification. by Buschelman B, Jones RN, Pfaller MA, Koontz FP and Doern GV published in Diagn. Microbiol. Infect. Dis. 1999; 35 (1): 89-91

Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results. by Biedenbach DJ, Jones RN, Lewis MT, Croco MA, and Barrett MS published in Diagn. Microbiol. Infect. Dis. 1999; 33 (4): 275-282

Accuracy of cefepime antimicrobial susceptibility testing results for Pseudomonas aeruginosa tested on the MicroScan WalkAway System. by Biedenbach DJ, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 33 (4): 305-307

Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and Etest methods. by Biedenbach DJ, Croco MA, Barrett TJ and Jones RN published in Eur. J. Clin. Microbiol. Infect. Dis. 1999; 18 (6): 428-431

In vitro evaluation of cefepime and other broad-spectrum β-lactams for isolates in Malaysia and Singapore medical centers. The Malaysia/Singapore Antimicrobial Resistance Study Group. by Biedenbach DJ, Lewis MT and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 277-283

In vitro evaluation of cefepime and other broad-spectrum β-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group. by Biedenbach DJ, Johnson DM and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 299-305

In vitro evaluation of cefepime and other broad-spectrum β-lactams in eight medical centers in Thailand. The Thailand Antimicrobial Resistance Study Group. by Biedenbach DJ, Johnson DM and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 325-331

Using multiple pharmacoeconomic methods to conduct a cost effective analysis of histamine H2-receptor antagonists. by McCoy S, Blayney-Chandramouli J and Mutnick A published in Am. J. Health Syst. Pharm. 1998; 55 (24 Supp 4) S8-12

The integration of quality assessment and a patient-specific intervention/outcomes program. by Mutnick AH, Sterba KJ and Szymusiak-Mutnick BA published in Pharm. Pract. Manag. Q. 1998; 17 (4): 25-36

Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: Analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). SENTRY Latin America Study Group. by Sader HS, Jones RN, Gales AC, Winokur P, Kugler KC, Pfaller MA and Doern GV published in Diagn. Microbiol. Infect. Dis. 1998; 32 (4): 289-301

Multicenter evaluation of the antimicrobial activity for six broad- spectrum β-lactams in Venezuela using the Etest method. The Venezuelan Antimicrobial Resistance Study Group. by Pfaller MA, Jones RN and Doern GV published in Diagn. Microbiol. Infect. Dis 1998; 30 (1): 45-52

National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. by Pfaller MA, Jones RN, Messer SA, Edmond MB and Wenzel RP published in Diagn. Microbiol. Infect. Dis. 1998; 30 (2): 121-129

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. by Pfaller MA, Marco F, Messer SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 30 (4): 251-255

National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. by Pfaller MA, Jones RN, Messer SA, Edmond MB and Wenzel RP published in Diagn. Microbiol. Infect. Dis. 1998; 31 (1): 327-332

Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates. by Pfaller MA, Lockhart SR, Pujol C, Swails-Wenger JA, Messer SA, Edmond MB, Jones RN, Wenzel RP and Soll DR published in J. Clin. Microbiol. 1998; 36 (6): 1518-1529

International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. by Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ and Messer SA published in J. Clin. Microbiol. 1998; 36 (7): 1886-1889

Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). by Pfaller MA, Jones RN, Doern GV and Kugler K published in Antimicrob. Agents. Chemother. 1998; 42 (7): 1762-1770

In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. by Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME and Hajjeh RA published in Antimicrob. Agents Chemother. 1998; 42 (12): 3242-3244

In vitro activity of cefepime and other broad-spectrum β-lactams tested against 129 mec A-negative Staphylococcus spp. isolates: A multicenter sample. by Marshall SA, Wilke WW, Chen YS, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 30 (1): 65-69

Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: Frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program. by Marshall SA, Wilke WW, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 30 (3): 205-214

Antimicrobial interactions of trovafloxacin and extended-spectrum cephalosporins or azithromycin tested against clinical isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia. by Johnson DM, Jones RN and Pfaller MA published in J. Antimicrob. Chemother. 1998; 42 (4): 557-559

Molecular analysis of TN1546 in Enterococcus faecium isolated from animals and humans. by Jensen LB, Ahrens P, Dons L, Jones RN, Hammerum AM and Aarestrup FM published in J. Clin. Microbiol. 1998; 36 (2): 437-442

International multicenter investigation of LB20304, a new fluoronaphthyridone. by Hohl AF, Frei R, Punter V, von Graevenitz A, Knapp C, Washington J, Johnson D and Jones RN published in Clin. Microbiol. Infect. 1998; 4 (5): 280-284

Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group. by Doern GV, Jones RN, Pfaller MA, Erwin M and Ramirez-Rhonda C published in Diagn. Microbiol. Infect. Dis. 1998; 30 (2): 113-119

Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. by Doern GV, Pfaller MA, Kugler K, Freeman J and Jones RN published in Clin. Infect. Dis. 1998; 27 (4): 764-770

The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada – 1997 results from the SENTRY Antimicrobial Surveillance Program. by Doern GV, Pfaller MA, Erwin ME, Brueggemann AB and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (4): 313-316

Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: Report from the SENTRY Antimicrobial Surveillance Program (1998). by DiPersio JR, Jones RN, Barrett T, Doern GV and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1998; 32 (2): 131-135

In vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp. by Croco MA, Biedenbach DJ, Pfaller MA, Doern GV, and Jones RN published in J. Antimicrob. Chemother. 1998; 42 (5): 672-673

In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates. by Cormican M, Corbett-Feeney G, Kelly S, Hughes D, Flynn J, and Jones RN published in Ir. J. Med. Sci. 1998; 167 (3): 155-159

Use of molecular and reference susceptibility testing methods in a multicenter evaluation of MicroScan dried overnight Gram-positive MIC panels for detection of vancomycin and high-level aminoglycoside resistances in enterococci. by Chen YS, Marshall SA, Winokur PL, Coffman SL, Wilke WW, Murray PR, Spiegel CA, Pfaller MA, Doern GV, and Jones RN published in J. Clin. Microbiol. 1998; 36 (10): 2996-3001

Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. by Biedenbach DJ, Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 31 (2): 349-353

BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens. by Biedenbach DJ, Barrett MS, Croco MA, and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (1): 45-50

Antimicrobial activity of gatifloxacin tested against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolone-resistant strains. by Biedenbach DJ, Beach ML and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (4): 307-311